NCT04206488View on ClinicalTrials.gov

A Study of JNJ-70033093 and Digoxin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

June 9, 2021

Study Completion Date

June 9, 2021

Conditions
Healthy
Interventions
DRUG

JNJ-70033093

Participants will receive JNJ-70033093 orally.

DRUG

Digoxin

Participants will receive digoxin orally.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04206488 - A Study of JNJ-70033093 and Digoxin in Healthy Participants | Biotech Hunter | Biotech Hunter